(Schizophrenia) |
(Mental Health - Depression) |
||
| Line 35: | Line 35: | ||
==Mental Health - Behavior Issues== | ==Mental Health - Behavior Issues== | ||
==Mental Health - Depression== | ==Mental Health - Depression== | ||
===2018 [https://pubmed.ncbi.nlm.nih.gov/29795403/ Nicotine normalizes cortico-striatal connectivity in non-smoking individuals with major depressive disorder]=== | |||
*In [[Abbreviations|'''MDD''']], acute nicotine administration normalized both pathways to the level of healthy controls, while having no impact on healthy controls. These results indicate that nicotine normalizes dysfunctional cortico-striatal communication in unmedicated non-smokers with MDD. | |||
*[https://sci-hub.st/10.1038/s41386-018-0069-x PDF Version] | |||
*Citation: Janes AC, Zegel M, Ohashi K, Betts J, Molokotos E, Olson D, Moran L, Pizzagalli DA. Nicotine normalizes cortico-striatal connectivity in non-smoking individuals with major depressive disorder. Neuropsychopharmacology. 2018 Nov;43(12):2445-2451. doi: 10.1038/s41386-018-0069-x. Epub 2018 Apr 19. PMID: 29795403; PMCID: PMC6180119. | |||
*Acknoledgements: This project was supported by the National Institute on Drug Abuse grants K10 DA029645 and K02 DA042987 (ACJ). DAP was partially supported by National Institute of Mental Health grant R37 MH068376. Over the past 3 years, DAP has received consulting fees from Akili Interactive Labs, BlackThorn Therapeutics, Boehringer Ingelheim, Pfizer and Posit Science, for activities unrelated to the current research. | |||
===2018 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129985/ Transdermal Nicotine for the Treatment of Mood and Cognitive Symptoms in Non-Smokers with Late-Life Depression]=== | |||
*[[Abbreviations|Late '''Life Depression (LLD)''']] is characterized by poor antidepressant response and cognitive dysfunction. Late life depression has no currently approved treatment that improves both its mood and cognitive symptoms. | |||
*We observed robust response (86.7%) and remission rates (53.3%). There was a significant decrease in MADRS (Montgomery-Asberg Depression Rating scale) over the study, with improvement seen as early as three weeks. We also observed improvement in apathy and rumination. We did not observe improvement on the CPT (Conners Continuous Performance Test), but did observe improvement in subjective cognitive performance and signals of potential drug effects on secondary cognitive measures of working memory, episodic memory, and self-referential emotional processing. | |||
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129985/pdf/nihms965043.pdf PDF Version] | |||
*Citation: Gandelman JA, Kang H, Antal A, Albert K, Boyd BD, Conley AC, Newhouse P, Taylor WD. Transdermal Nicotine for the Treatment of Mood and Cognitive Symptoms in Nonsmokers With Late-Life Depression. J Clin Psychiatry. 2018 Aug 28;79(5):18m12137. doi: 10.4088/JCP.18m12137. PMID: 30192444; PMCID: PMC6129985. | |||
*Acknowledgements: This research was supported by NIH grant K24 MH110598 and CTSA award UL1TR000445 from the National Center for Advancing Translational Sciences. The sponsor provided funding for the study but did not influence the design or conduct of the study. | |||
===2002 [https://pubmed.ncbi.nlm.nih.gov/11995405/ Relationship between mood improvement and sleep changes with acute nicotine administration in non-smoking major depressed patients]=== | |||
*Acute administration of nicotine patches produced rapid eye movement sleep (REM) increases in non-smoking major depressed patients as well as clinical improvement in mood. Antidepressant effect was also observed after four continuous days of nicotine administration. | |||
*Citation: Salin-Pascual RJ. Relationship between mood improvement and sleep changes with acute nicotine administration in non-smoking major depressed patients. Rev Invest Clin. 2002 Jan-Feb;54(1):36-40. PMID: 11995405. | |||
===1999 [https://link.springer.com/article/10.1007/s002130050879 Antidepressant effects of nicotine in an animal model of depression]=== | |||
*Animal Study | |||
*Epidemiological studies indicate a high incidence of cigarette smoking among depressed individuals. Moreover, individuals with a history of depression have a much harder time giving up smoking. It has been postulated that smoking may reflect an attempt at self-medication with nicotine by these individuals. | |||
*The data strongly implicate the involvement of central nicotinic receptors in the depressive characteristics of the [[Abbreviations|'''FSL''']] rats, and suggest that nicotinic agonists may have therapeutic benefits in depressive disorders | |||
*[https://sci-hub.st/https://doi.org/10.1007/s002130050879 PDF Version] | |||
*Citation: Tizabi, Y., Overstreet, D., Rezvani, A. et al. Antidepressant effects of nicotine in an animal model of depression. Psychopharmacology 142, 193–199 (1999). https://doi.org/10.1007/s002130050879 | |||
*Acknowledgements This work was supported in part by the Department of Pharmacology, Howard University, VAMC and Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA. | |||
*Keywords: Key words Nicotine · Nicotinic receptor · FSL and FRL rats · Animal model of depression | |||
===1998 [https://pubmed.ncbi.nlm.nih.gov/9592048/ A novel effect of nicotine on mood and sleep in major depression]=== | |||
*Transdermal nicotine patches increased REM sleep in normal volunteers and depressed patients during 4 days of continuous administration. In addition, a significant improvement of mood was observed in depressed patients. Nicotinic mechanisms may be involved in depression. These findings suggest that nicotine receptor activation may be important in major depression and shows for the first time that nicotine patches may be useful in the treatment of depression. | |||
*[https://sci-hub.st/10.1097/00001756-199801050-00012 PDF Version] | |||
*Salín-Pascual RJ, Drucker-Colín R. A novel effect of nicotine on mood and sleep in major depression. Neuroreport. 1998 Jan 5;9(1):57-60. doi: 10.1097/00001756-199801050-00012. PMID: 9592048. | |||
*ACKNOWLEDGEMENT: This work has been supported by the following grants: DGAPA-UNAM IN -200895 to R.J.S-P. | |||
===1996 [https://pubmed.ncbi.nlm.nih.gov/9746444/ Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression]=== | |||
*A high frequency of cigarette smoking has been reported among individuals with major depression. | |||
*Results of the visual analog scale and [[Abbreviations|'''HAM-D''']] showed a significant improvement in depression after the second day of nicotine patches. | |||
*Citation: Salín-Pascual RJ, Rosas M, Jimenez-Genchi A, Rivera-Meza BL, Delgado-Parra V. Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. J Clin Psychiatry. 1996 Sep;57(9):387-9. PMID: 9746444. | |||
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== | |||
* When chronically taken, nicotine may result in: (1) positive reinforcement, (2) negative reinforcement (mood normalization) (other issues and diseases mentioned in study) | |||
*[https://sci-hub.st/10.1111/j.1360-0443.1991.tb01810.x PDF version] | |||
*Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921. | |||
*Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation. | |||
==Mental Health - Schizophrenia== | ==Mental Health - Schizophrenia== | ||
edits